The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| JANX | -52.73% | N/A | N/A | -3% |
| S&P | +16.9% | +95.99% | +14.39% | +60% |
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.54M | -106.4% |
| Gross Margin | -16.17% | 0.0% |
| Market Cap | $1.37B | -37.1% |
| Market Cap / Employee | $13.27M | -57.8% |
| Employees | 103 | 49.3% |
| Net Income | -$33.86M | -468.2% |
| EBITDA | -$44.58M | -234.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $52.45M | 257.7% |
| Accounts Receivable | $7.50M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.32M | -8.4% |
| Short Term Debt | $1.87M | 14.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -12.26% | -3.7% |
| Return On Invested Capital | -29.35% | -21.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$24.29M | -140.1% |
| Operating Free Cash Flow | -$23.81M | -137.6% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.60 | 4.27 | 1.56 | 1.35 | -59.23% |
| Price to Sales | 190.19 | 287.38 | 178.70 | 3257.28 | 2060.16% |
| Price to Tangible Book Value | 3.60 | 4.27 | 1.56 | 1.35 | -59.23% |
| Enterprise Value to EBITDA | -52.28 | -71.58 | -19.69 | -10.23 | -91.78% |
| Return on Equity | -12.0% | -10.1% | -9.3% | -12.8% | 39.29% |
| Total Debt | $23.43M | $23.03M | $22.61M | $22.19M | -6.84% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
